Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Steroid 5-alpha-reductase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | conserved hypothetical protein | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0053 | 0.5 | 0.5 |
Entamoeba histolytica | trans-2,3-enoyl-CoA reductase, putative | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0053 | 0.5 | 0.5 |
Brugia malayi | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | 0.0053 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.5 | 0.5 |
Echinococcus granulosus | 3 oxo 5 alpha steroid 4 dehydrogenase C terminal | 0.0053 | 0.5 | 0.5 |
Entamoeba histolytica | steroid 5-alpha reductase, putative | 0.0053 | 0.5 | 0.5 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Schistosoma mansoni | synaptic glycoprotein sc2 related | 0.0053 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Entamoeba histolytica | 3-oxo-5-alpha-steroid 4-dehydrogenase domain-containing protein | 0.0053 | 0.5 | 0.5 |
Plasmodium falciparum | polyprenol reductase, putative | 0.0053 | 0.5 | 0.5 |
Schistosoma mansoni | synaptic glycoprotein sc2 related | 0.0053 | 0.5 | 0.5 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Giardia lamblia | Synaptic glycoprotein SC2 | 0.0053 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0053 | 0.5 | 0.5 | |
Echinococcus granulosus | synaptic glycoprotein sc2 | 0.0053 | 0.5 | 0.5 |
Plasmodium falciparum | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0053 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0053 | 0.5 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0053 | 0.5 | 0.5 |
Echinococcus multilocularis | 3 oxo 5 alpha steroid 4 dehydrogenase, C terminal | 0.0053 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0053 | 0.5 | 0.5 |
Leishmania major | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein | 0.0053 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0053 | 0.5 | 0.5 |
Echinococcus multilocularis | synaptic glycoprotein sc2 | 0.0053 | 0.5 | 0.5 |
Plasmodium vivax | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0053 | 0.5 | 0.5 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0053 | 0.5 | 0.5 |
Plasmodium vivax | polyprenol reductase, putative | 0.0053 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 8.8 nM | Inhibitory actitivity against Steroid 5-alpha-reductase in prostates from male rats | ChEMBL. | 7636849 |
IC50 (binding) | = 8.8 nM | Inhibitory actitivity against Steroid 5-alpha-reductase in prostates from male rats | ChEMBL. | 7636849 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.